aTYR PHARMA INC ATYR
We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains derived from all 20 tRNA synthetases.
Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ILDs are predominantly immune-mediated disorders that are characterized by chronic inflammation, which can lead to progressive fibrosis of the lung. There are limited treatment options for ILD and there remains a high unmet medical need. Sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated ILD (SSc-ILD) are two major forms of ILD. The U.S. Food and Drug Administration (FDA) has granted efzofitimod orphan drug designations for the treatment of sarcoidosis and for the treatment of SSc, and Fast Track designations for the treatment of pulmonary sarcoidosis and for the treatment of SSc-ILD. The European Commission has granted efzofitimod orphan drug designations for the treatment of sarcoidosis and for the treatment of SSc, based on the opinion of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). The Pharmaceutical and Medical Devices Agency (PMDA) has granted efzofitimod orphan drug designation for the treatment of sarcoidosis to Kyorin Pharmaceutical Co., Ltd. (Kyorin), our partner in Japan.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.4M | $0 | $10.5M | $422.0K | — | — | — |
| R&D | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M | $42.8M |
| SG&A | $17.6M | $13.8M | $13.0M | $14.0M | $10.8M | $9.1M | $9.4M | $12.4M | $17.1M | $15.1M |
| Total operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M | $26.4M | $23.4M | $32.8M | $47.1M | $57.9M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M | -$15.9M | -$23.0M | -$32.8M | -$47.1M | -$57.9M |
| Pre-tax income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M | -$16.2M | -$23.8M | -$34.5M | -$48.2M | -$57.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $49.0K |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M | -$16.2M | -$16.2M | -$34.5M | -$48.2M | -$57.9M |
| EPS, basic | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | — | — | — | — |
| EPS, diluted | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.11 | -26.13 | -2.44 |
| Shares, diluted (wtd. avg.) | 93.0M | 74.3M | 53.6M | 28.4M | 19.1M | 9.2M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.7M | $11.1M | $22.5M | $10.0M | $2.3M | $17.0M | $9.2M | $23.0M | $21.1M | $38.4M |
| Short-term investments | $67.9M | $61.1M | $75.6M | $56.2M | $105.6M | $14.7M | $21.9M | $26.6M | $64.0M | $33.8M |
| Total current assets | $80.2M | $82.0M | $103.0M | $80.9M | $113.6M | $35.5M | $31.9M | $50.8M | $87.0M | $74.8M |
| Property, plant and equipment | $4.3M | $4.8M | $5.5M | $3.1M | $543.0K | $899.0K | $1.3M | $1.9M | $2.3M | $1.4M |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M | $38.7M | $36.2M | $52.7M | $89.4M | $80.5M |
| Accounts payable | $3.9M | $4.3M | $3.5M | $3.1M | $1.0M | $1.4M | $847.0K | $1.0M | $2.3M | $2.6M |
| Short-term debt | — | — | — | — | — | — | $8.7M | $7.8M | $5.0M | $339.0K |
| Total current liabilities | $15.1M | $15.0M | $16.4M | $13.9M | $6.0M | $5.9M | $12.9M | $10.8M | $10.4M | $8.5M |
| Long-term debt | — | — | — | — | — | — | — | $8.3M | $14.7M | $9.2M |
| Retained earnings | -$606.2M | -$532.0M | -$468.0M | -$417.6M | -$372.3M | -$338.5M | -$322.3M | -$298.7M | -$264.2M | -$216.0M |
| Total equity | $67.5M | $70.0M | $90.5M | $71.3M | $109.1M | $31.5M | $21.0M | $33.6M | $64.2M | $62.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M | -$15.3M | -$20.0M | -$31.1M | -$42.4M | -$52.9M |
| Depreciation and amortisation | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K | $569.0K | $635.0K | $746.0K | $713.0K | $900.0K |
| Capital expenditure | $77.0K | $65.0K | $4.2M | $1.6M | $192.0K | $202.0K | $79.0K | $594.0K | $1.3M | $600.0K |
| Investing cash flow | -$5.1M | $17.2M | -$20.1M | $47.2M | -$91.6M | $6.9M | $4.9M | $37.2M | -$27.6M | $33.5M |
| Financing cash flow | $66.0M | $39.9M | $66.2M | $5.5M | $110.0M | $16.1M | $1.3M | -$4.2M | $52.7M | $4.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001339970-26-000008.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $422.0K | $10.5M | $0 | $10.4M | $353.0K | $235.0K | $190.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$57.9M | -$48.2M | -$34.5M | -$16.2M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Delisting notice Item 3.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |